Philadelphia chromosome

GPTKB entity

Statements (83)
Predicate Object
gptkbp:instance_of gptkb:DNA
gptkbp:associated_with gptkb:chronic_myeloid_leukemia
gptkb:Oncology
gptkb:sports_equipment
gptkb:guidelines
treatment adherence
clinical trials
community outreach
patient outcomes
patient registries
public health initiatives
research funding
supportive care
disease progression
epidemiological studies
treatment response
cell signaling pathways
genomic studies
epigenetic changes
genetic counseling
oncogenes
precision medicine
international guidelines
tyrosine kinase activity
patient monitoring
therapeutic resistance
survivorship issues
imatinib resistance
clinical trials design
myeloproliferative disorders
leukemogenesis
clonal evolution
relapse rates
gptkbp:can_detect PCR
FISH
gptkbp:cause gptkb:fusion
gptkbp:discovered_by gptkb:1973
https://www.w3.org/2000/01/rdf-schema#label Philadelphia chromosome
gptkbp:influences treatment options
gptkbp:involves chromosome 9
chromosome 22
t(9;22)(q34;q11)
gptkbp:involves_gene gptkb:ABL1
BCR
gptkbp:is_found_in gptkb:hematopoietic_stem_cells
gptkbp:is_linked_to gptkb:scientific_collaborations
gptkb:Health_Insurance
palliative care
patient education
quality of life
advocacy efforts
data sharing
genetic testing
health disparities
multidisciplinary teams
family history
biostatistics
healthcare costs
risk stratification
survival rates
targeted therapy
tumor suppressor genes
molecular genetics
chromosomal translocation
therapeutic targets
genetic instability
increased cell proliferation
long-term outcomes
poor prognosis
research advancements
clinical management
inhibition of apoptosis
biological markers
biomarker development
molecular monitoring
secondary mutations
gptkbp:is_recognized_as gptkb:Philadelphia,_Pennsylvania
gptkbp:is_recognized_by cytogenetic analysis
gptkbp:is_targeted_at tyrosine kinase inhibitors
gptkbp:resulted_in gptkb:BCR-ABL_fusion_protein
gptkbp:bfsParent gptkb:chronic_myeloid_leukemia
gptkb:Oncology
gptkbp:bfsLayer 4